Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 4Pancreatic Neoplasms 2Rectal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Head and Neck Neoplasms 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Esophageal Squamous Cell Carcinoma 1Esophageal 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Apatinib Combined 1Advanced Pancreatic Cancer 1

Interventions

Gemcitabine 6130-nm albumin-bound paclitaxel 5Albumin-Bound Paclitaxel 4Taxes 3S 1 (combination) 3Drug Therapy 2toripalimab 1surufatinib 1paricalcitol 1nimotuzumab 1irinotecan sucrosofate 1gimeracil 1envafolimab 1endostar protein 1camrelizumab 1cabiralizumab 1apatinib 1Tegafur 1Radiosurgery 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Immunotherapy 1IMM-101 1Fluorouracil 1Endostatins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Pancreatic Cancer × gimeracil × Clear all
NCT03415802 2021-02-01

Efficacy and Safety of Nab-Paclitaxel Plus S-1 in the First-line Treatment of Advanced Pancreatic Cancer

ChineseAMS

Phase 2 Completed
32 enrolled
Gastrointestinal

Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡